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Loss of maternal measles antibody in black South
African infants in the first year of life
implications for age of vaccination
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Summary
In order to investigate the feasibility of measles vaccination
before the age of 9 months the duration of passive immunity
against measles was estimated by conducting a longitudinal
study of measles antibody levels in 20 black neonates
delivered at term. Measles serum antibody (lgG) was mea-
sured by enzyme-linked immunosorbent assay in the mother
at childbirth and on consecutive samples taken from the
infants from birth until 9 months of age. Protective measles
antibody level was defined as > 200 mlU. Unprotective levels
were found in 88% (95% confidence interval (Cl) 81 - 99%) of
6-month-old infants, while at 9 months all were susceptible.
The mean antibody level was 192 mlU (Cl 104 - 348%) at 4
months; 34 mlU (Cl 15 - 73%) at 6 months and 13 mlU (Cl
6-24%) at 9 months of age. Our data support the recent
World Health Organisation recommendation to immunise
children in developing countries at 6 months with the 'high titre'
Edmonston-Zagreb measles vaccine, since most infants in
our study had lost passive immunity against measles by this
age.
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Measles remains one of the most important infectious diseases
in children born in poor socio-economic conditions, 1 where it
is well known to be a prominent cause of morbidity and
mortality.2-7 The high measles mortality among infants is
partially attributable to early age at exposure to the virus and
geographical differences in the duration of passive immunity.S-15
The age-specific incidence rate and other aspects of measles
in developing countries are different from the pattern in
developed countries. On the basis of serological evidence,
children in the USA are vaccinated at 15 months, since the
disease is uncommon in younger children. 16 In specific regions
of South Mrica 20 - 45% of cases of measles occur in black
infants under the age of 8 months.s At this age, vaccination is
hampered because circulating maternal antibodies neutralise
the conventional Schwarz vaccine. It is therefore pertinent to _
establish, on the basis of serological evidence, the optimum
age at which to immunise these infants against measles.
Data on measles IgG antibody levels measured by enzyme-
linked immunosorbent assay (ELISA) in newborn black infants
and the subsequent decline and disappearance of the maternally
acquired specific antibodies over time are reported.
Subjects and methods
The study population comprised 20 normally delivered new-
born infants (half of whom were male) from the black com-
munity of KwaMashu township, Durban. Serum samples
were obtained during a trial using acellular pertussis vaccine
(conducted by A. Ramkissoon, H. M. Coovadia and W. E. K.
Loening). All babies were delivered at term. Serial blood
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The predicted values were obtained from the centrai distribution function of a






















































































curve relating changes in antibody level to age and to demon-
strate the changing proportions of children (whose antibody
level remained above 200 mID). In both analyses the reliability
of predictions, in terms of confidence limits, must be made in
relation to 'between-child' variability.' Naturally, any extra-
polation of these results to a wider population of children
assumes the sample of 20 to represent that wider population.
(a) The mean curve comparing amibody levels wich age. We
took the log (OD) value for each child and fitted a cubic
equation through the 5 points. While a sigmoid curve may
represent the underlying relationship better, the data were
insufficient to allow the necessary parameter estimation. As a
means of interpolation, however, the cubic polynomial seemed
satisfactory. The means and standard error of the predicted
values for all 20 children were calculated for each of the 5
points. The c-distribution was used to calculate the 95%
confidence limits. Finally, the predicted values and confidenc.e
limits were transformed back to mID. The results appear in
Table I and Fig. 1. Note that the crosses on the graphs are
observed median values. 18
Serology
Measles IgG antibody was detected by ELISA, which was
supplied in a kit form by Behring (West Germany). Measles
antigen-coated plates were all supplied from the same batch
(OSOK 02103 lot No. 406446A) as was the anti-human IgG-
alkaline phosphatase conjugate (OSDH 04/05 lot No. 410955A)
and supplementary agents (lot 19604). Results are expressed as
mIU/m! with reference to the World Health Organisation
standard anti-measles serum (obtained as a gift from the
WHO). An optical density (OD) of < 0,2 (equivalent to < 34
mlU) was considered negative. Each child's and the respective
mother's serum was processed in duplicate and always included
in the same tests. All sera specimens were tested on the same
day in the same tests. All sera specimens were tested on the
same day in order to avoid any bias in sample testing due to
the intrinsic variability of ELISA to either the environment or
technical variation. International and local standards were
included as controls (2 of which were kindly donated by Dr
Roger Glass, Centers for Disease Control, Atlanta, Georgia,
USA). Seropositivity was defmed according to the persistence
of antibody. 17 For this reason, seropositivity was defmed as >
200 mIU/m! at any time after birth. (Dr N. Halsey - personal
communication; based on unpublished data from Dr P.
Albrecht's laboratory.)
samples were obtained by venepuncture from these same
infants at birth, 2, 4, 6 and 9 months of age.
Nutritional status, using the weight-for-age, height-for-age
and weight-for-height criteria of the US National Center for
Health Statistics (NCHS) standards, was assessed at each visit.
The parity of the mother and type of feeding (breast or bottle)
was also recorded. The age and vaccination status of the
mother was not recorded.
The following common problems of infancy were detected
in these babies during the period of follow-up: impetigo (10
infants), upper respiratory tract infection (5), otitis media (4),
lower respiratory tract infection (3), diarrhoea (3), conjunctivitis
(1), febrile convulsion (1) and post-vaccinial transient hypotonia
(1).
Ethical approval
The acellular pertussis vaccine trial was approved by the
Ethics Committee of the Faculty of Medicine, University of
Natal. Informed consent was obtained from the parent(s) or
guardian who voluntarily consented to their child being entered
into ·study after due explanation of the object of the trial and
the number of blood specimens required.
Statistical methods
I. Polynomial regression was used to determine the relation-
ship between mlU and OD readings obtained from the WHO
reference serum. It was found that the parabola, given by
VmIU =-3,1l61 + 27,5328 (OD) + 9,3737 (OD)2, described
the relationship that existed between mID and OD readings.
The adjusted coefficient of determination was r2 = 0,99, i.e.
99% of the variation in mlU is explained by the variation in
OD.
The utility of the above equation is limited to the observed
range in OD values, i.e. from 0 to 1,6, since the latter OD
reading was the maximum reading obtained for the patient
sera tested.
Results are reported to the nearest whole number.
2. The data comprised a classic repeated measures set in
that each of the 20 children was measured on 5 occasions. The
purpose of the statistical analysis was to determine an average
(b) The proporcion of children wich amibody level above 200
mIU. For each age the mean log (OD) predicted value and
standard error were calculated. Assuming a normal distribution
in the log transformed data, the probability of an individual
log (OD) value exceeding the equivalent of 200 mID was
estimated. Confidence limits were calculated using the boot-
strap method. The probability predictions and confidence
limits are shown in Table 11 and Fig. 2. 19
Mother's antibody, height and weight were included as co-
variates in a multivariate analysis.
Results
Of the 6-month-old infants 88% (confidence interval (Cl)
81 - 93%) and of 9-month-old infants 100% (Cl 99 - 100%) had
reached unprotective levels « 200 mID) of measles IgG
-
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Fig. 1. Proportion of children with antibody level> 200 mlU. Fig. 2. Mean antibody level by age.
Discussion
In the black population investigated, passively transferred
measles antibody of maternal origin seems to wane earlier
The predicted antibody levels are mean values from 20 children, with the value for
each child being predicted by an equation determined by the method of least
squares on log-transformed data. Calculations of confidence limits assume that the
log-transformed data have a normal distribution.
antibody (Table I, Fig. 1). It appeared that the decline of
maternal antibody began after 2 months of age, thereafter this
decline was rapid, reaching a plateau at about 6 months.
Six-month-old infants had measles IgG antibody levels of
35 mlU (Cl 15 - 73%), while in 9-month-olds this level was 13
mlU (Cl 6 - 24%) (Table 11, Fig. 2).
Neither the mother's antibody level nor height and weight,
parity, and type of feeding had any influence on loss of passive
immunity against measles.
during infancy than was shown by initial studies on which
vaccination policy was based in Africa.8,20,21 This may have
been parrly influenced by the common infections seen in these
infants. Furthermore, the level of maternal antibody was not
an imporrant factor in determining seropositivity levels over
time. Anthropometric measurements (height and weight), parity
and type of feeding had little, if any, effect on the loss of
measles maternal antibody.
The reasons for the early loss of natural protection against
measles are not clear. Several factors have been shown to play
a role in the decrease over time of protection against measles
by maternal antibody.15.21,22
Geographical differences may parrly account for the dura-
bility of passive immunity. Results have varied in different
parts of Africa. The proportion of seronegative children reached
90% by the end of 4 months of age in Gabon;23 7 months in
Cong020 and 8 months in rural Kenya8 and in Lagos, Nigeria. 15
Outside Africa most of the available data come from the
Americas. l2,I' Halsey er a/. I ' in Haiti, found that 8 - 9 months
was the age at which maternally transferred antibody was no
longer present in more than 80% of the population, and
satisfactory seroconversion rates to measles vaccination were
obtained. In Bristol, UK, although limited by small sample
size, Jenks er a/. 22 found that maternal protection is lost in the
majority of children by 8 months; and Bhaskaram er al. 6 in
India found that it was lost by 9 months of age. These
variations can be explained by epidemiological and demo-
graphic differences among communities (for example rate of
decay of maternally derived antibody; age-specific mortality; -
rate of infection; and the net birth rate), which are important
in the transmission of measles virus. 24
An important consideration, which makes comparisons diffi-
cult, is the techniques used in different studies. The haemag-
glutination inhibition test is known to have poor sensitivity
and does not give meaningful quantitative results, particularly
for low-antibody titres. The ELISA is similarly not a good
measure of maternal measles antibody because it measures the
existence of antibody to viral nucleocapsids and other non-
infectious viral components as well as to infectious viral
particles,25 whereas the plaque inhibition (PI) technique has
been shown to yield results 4 times more sensitive and precise
than the HI test, but it is a complex and difficult technique for
routine use. Because of these differing sensitivities, serological
data should be reported in comparison with data derived using
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have done this in order to facilitate comparison of our results
with other studies, but have not utilised PI.
Unlike other fmdings,26 maternal antibody levels in this
study had little effect on the rate of decay of passively trans-
ferred antibody over time. This could be as a result of a type 2
error, since we were unable to detect maternal factors that
might provide an explanation. All subjects resided in the same
district, most were from the same low-income group and most
probably had had natural infection, since there was no
documentary proof of vaccination. None of the other mother
and child characteristics shown to influence rate of decay of
passive antibody, such as weight and height, parity, and type
of feeding, had an effect in this study.21
We have recently shown27 that the standard dose
Edmonston-Zagreb (EZ) measles vaccine and the currently
used Schwarz vaccine are unsatisfactory in immunising children
aged 4 - 8,5 months. In the light of this and the recent WHO
recommendation28 on measles immunisation, the high-dose EZ
measles vaccine will be successful in immunising 6-month-
olds in our population, since at this age 88% are susceptible to
measles.
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